Misonix BoneScalpel(TM) Subject Of New Clinical Paper
FARMINGDALE, N.Y., Jan. 29, 2013 /PRNewswire/ — Misonix, Inc. (NasdaqGM: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, was cited in a clinical paper accepted for publication by “The Laryngoscope,” a prestigious, peer-reviewed journal circulated to leading ear, nose, throat and reconstructive surgeons, entitled “Piezoelectric BoneScalpel Osteotomies in Osteocutaneous Free Flaps,” authored by Wick, et al, from the Department of Otolaryngology-Head and Neck Surgery, University Hospitals Ear, Nose, and Throat Institute; University Hospitals Case Medical Center, Cleveland, Ohio. Free flaps, in this instance, refer to harvested bone and soft tissue from donor sites used in reconstructive surgery of the head and neck.
Among the conclusions of the study, it was noted that the Misonix® BoneScalpel Ultrasonic Bone Cutter offers a safe and efficient method to create precise cuts during the harvest of bone to be used for reconstructive surgery of the head and neck, generally required as a result of cancer surgery. Primary advantages of the device include better tactile control, precise osteotomies (cuts through bone), a minimal learning curve for the surgeons, and theoretic protection of vital soft tissue such as vascular structures.
The Misonix® BoneScalpel, which was used to perform the study, is a novel ultrasonic osteotome (bone cutting device) used for safe, tissue-selective bone dissection that encourages non-fragmented bone removal and refined osteotomies while sparing elastic soft tissue structures. Most users report that the surgical field is relatively bloodless and clean. Loss of viable bone is minimal and controllable. The BoneScalpel has been used extensively for bone removal in the cervical, thoracic and lumbar spine, including deformity surgery.
“We are proud to be cited by a prestigious peer-reviewed journal for yet another positive clinical experience with the Misonix BoneScalpel when used in advanced head and neck surgery,” said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. “It is our privilege to provide state-of-the-art head and neck surgery technology to prestigious institutions such as Cleveland’s University Hospitals.”
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contacts Misonix Contact: Lytham Partners, LLC Richard Zaremba Robert Blum, Joe Dorame, Joe Diaz 631-694-9555 602-889-9700 email@example.com firstname.lastname@example.org
SOURCE Misonix, Inc.